Está en modo consejo Apagar

NewAmsterdam Pharma, ordinary share
NL00150012L7, NAMS

Agregación de la acción a WL
NewAmsterdam Pharma, país — Países Bajos
Faltan datos de licitaciones
Puede cambiar la visualización de datos gráfico | tabla
Fuente de información – “Bolsa de Moscú”, S.A.P. La difusión posterior de la información bursátil está prohibida sin acuerdo previo con “Bolsa de Moscú”, S.A.P.
Fuente de información – “Bolsa de Moscú”, S.A.P. La difusión posterior de la información bursátil está prohibida sin acuerdo previo con “Bolsa de Moscú”, S.A.P.
desde
hasta
Complemento
complemento Cbonds
API
datos sobre bonos por api
Es necesario autorizarse
Es necesario obtener acceso
Más de 2,500 registros han sido encontrados, por favor especifique su consulta
No hay datos para el período elegido

Últimas cotizaciones

explore la más completa base de datos

800 000

bonos globalmente

Más de 400

fuentes de precios

80 000

acciones

9 000

ETF

siga su portfolio de la manera más eficiente
búsqueda de bonos
Watchlist
Excel ADD-IN

Emisor

Perfil
NewAmsterdam Pharma operates as a pharmaceutical company. The Company focuses on the research and development of transformative therapies for cardio-metabolic diseases. NewAmsterdam Pharma serves customers in the Netherlands.
  • Emisor
  • Nombre completo del deudor / emisor
    NewAmsterdam Pharma Co NV
  • Industria
    Fabricación de medicina y biotecnología

Estados Financieros NIIF / US GAAP

2024
2023
2022
Es necesario autorizarse
Es necesario obtener acceso

La acción forma parte del indice

Indicadores

Noticias

09/05/2024 NewAmsterdam Pharma: Results Of Operations And Financial Condition, Financial Statements And Exhibits
28/03/2024 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
04/03/2024 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
28/02/2024 NewAmsterdam Pharma: Of This Current Report On Form, Financial Statements And Exhibits
13/02/2024 NewAmsterdam Pharma: The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act. The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
Todas las noticias de la organización

Otras acciones y recibos de depósito

Tenedores

Líderes de la industria

Hay que registrarse para recibir el acceso.